Febuxostat, Allopurinol Jockey for Role in Gout : Allopurinol remains the first-line agent in gout treatment, despite issues of kidney clearance.

The Bottom Line

What does all this mean for the number of gout patients who should get febuxostat? On the low end, estimates range down to fewer than 5%, according to Dr. Simkin, whose total is mostly patients who are intolerant of allopurinol. On the high end, Dr. Schlesinger estimated that “millions” of U.S. gout patients need febuxostat, includinged all gout patients with chronic kidney disease, those who don't respond to a 300 mg/day allopurinol dosage, and those who are allopurinol intolerant.

'Millions' of U.S. gout patients, including those with renal problems, could benefit from febuxostat.

Source Dr. Schlesinger